Owing to its low costs and favourable regulatory environment, Asia has become the fastest growing pharmaceutical market in the recent years. The rapid growth of Asia in the global pharmaceutical industry offers new opportunities for the industry players in the region.
The sheer number of residents in countries like China and India as well as a rapidly aging population make Asia an attractive target for global health care companies. Within healthcare, pharmaceuticals are the greatest growth engine. Pharmaceutical companies recognize that rising personal income have made health care more accessible and affordable in China.
According to some estimates while over the next five years, the pharmaceutical industry is expected to grow by three to six per cent in developed markets such as the U.S, in emerging economies, including China and India it would grow up by 14 to to 17 per cent.
A massive effort by the Chinese government to make health care more affordable to its residents is opening up new opportunities for foreign drugmakers. U.S. companies, including Pfizer and Eli Lilly, have beefed up their presence in this market.
A study by CMR International, a Thomson Reuters business had pointed out last year that pharmaceutical companies in the Asia Pacific region are increasingly adapting their business models from the production of generic drugs towards more high-risk, high-return research and development.
The changing picture was pointed in the first edition of the 2010 Asia Pacific R&D Factbook, which finds increased clinical trial activity, patent challenges, and molecular development in the region.
"Whilst the proportion of global R&D expenditure allocated to Asia Pacific was less than one percent in 2009, these trends show a growing focus on these activities," said Hans Poulsen, head of life sciences consulting at Thomson Reuters.
Global figures for clinical trial recruitment also highlighted a dramatic shift away from the United States and toward Asia Pacific. The number of new molecules in development by generic companies, particularly in India also , reflects a strong inclination to invest in R&D. And the number of patent challenges in the region indicates an increasingly aggressive approach to securing market share.
INTERPHEX Asia, an annual trade platform for the pharmaceutical manufacturing industry which will be held from May 30 - 31, 2011 at SUNTEC Convention Centre, Singapore provides opportunities for major pharmaceutical and biopharmaceutical industry players in Asia to demonstrate the latest technologies and expertise. It helps international and regional suppliers to establish and grow partnerships with multinational pharmaceutical manufacturers.
INTERPHEX Asia, part of the worldwide INTERPHEX family of events, is the strategic platform for international equipment and service providers to showcase their capabilities face-to-face to regional pharmaceutical manufacturing players in Asia.
With multinational manufacturers looking for new opportunities to expand their operations within Asia as well as the increased opportunities for incumbent manufacturers to explore collaboration in contract as well as generics manufacturing – INTERPHEX Asia 2011 provides equipment and service providers the business development opportunities to gain high market share in Asia.
INTERPHEX Asia is the only event dedicated to the pharmaceutical manufacturing industry in Asia. Bringing together the pharmaceutical manufacturing professionals in the Asia-Pacific region and international suppliers, the event is the platform to network, meet industry suppliers and get updates on industry developments.
It is a one-stop platform for international and regional suppliers to establish and grow their foothold to cater to the developing and upcoming drug development and manufacturing activities by multinational pharmaceutical and biopharmaceutical manufacturers in Asia.
INTERPHEX Asia 2011 provides the business development opportunities to gain high market share and expand operations in Asia. It enables one to connect with the pharmaceutical manufacturing industry,showcase your product/service/technology to more than 1,200 attendees,generate potential sale leads in this targeted industry event,gain new customer prospects,renew connections with your existing customers,launch new products/services and cutting edge technology and network within the pharmaceutical manufacturing industry
The event is expected to draw more than 120 exhibiting companies from 20 countries such as Italy, Germany, Japan, United Kingdom and United States who will be showcasing their capabilities face-to-face to regional pharmaceutical manufacturing players in Asia. Over 1,000 visitors from 20 countries are expected at the event to source for new suppliers and view the latest cutting edge pharmaceutical manufacturing technology.
The product categories that will be showcased include analytical equipment & services,automation and IT systems,biopharmaceutical/ biotechnology,bioinformatics,cleanroom equipment & supplies,CROs,contract service providers,environmental services,instruments and controls,labelling, coding and marking,packaging systems & materials,plant engineering and maintenance,QA/QC systems and services,raw materials/ingredients,validation and compliance support,logistics – warehousing and distribution
The INTERPHEX CentreStage is a technology showcase for demonstration of the latest products and technologies from international and regional suppliers. It enables a participant to discover and keep abreast on new technology developments from industry suppliers who will share their technical expertise in their relevant area.
INTERPHEX Asia will be held in association with the ISPE Singapore Conference 2011. The conference will provide delegates with the opportunity to discuss and exchange views relating to the manufacturing processes of the pharmaceutical industry.
With the theme of “Pharmaceutical Manufacturing in Asia – Achieving Operational Excellence”,the ISPE Singapore Conference 2011 aims to address current regulatory and manufacturing issues which will provide participants with an in-depth learning opportunity and to gain and update industry knowledge. The conference is expected to draw more than 350 participants from over 20 countries who will convene to gain insights and enhance their industry knowledge.
Through a combination of interactive workshops, industry keynotes and breakout discussions delivered by more than 20 international and regional speakers, participants will be able to discuss and exchange views, ideas and insights pertaining to the manufacturing processes such as:
- Behavioural GMP – Breaking the Fire-Fighting Cycle
- Biotechnologies and disposable Equipment: Impact on Facilities Design
- Contract Manufacturing: Opportunities, challenges and trends – a MNC perspective
- Designing & Validating a PIC/S compliant manufacturing facility
- Energy reduction in filter systems for pharma applications
- Quality Risk Management: Applications in Regulatory Filing
- Strategy for Success – Surviving GMP Inspection by MHRA
- The Road to Commercialisation for a Malaysian Injectables Fill and Finish CMO
The conference will feature two workshops that focus on “Behavioural GMP – Breaking the Fire-Fighting Cycle” and “Designing and Validating a PIC/S Compliant Manufacturing Facility”. Conference participants will be able to register for two workshops as both workshops will be conducted in the morning and afternoon session. To provide more flexibility and generate in-depth discussions within an intimate group, there will be a limit to the number of seats per workshop session.
The conference participants will also be able to visit the state-of-the-art pharmaceutical manufacturing facilities located in Singapore such as Institute of Chemical Engineering, MSD Secondary Non-Sterile Operations and Roche Singapore Technical Operations Building (CHO Plant).
The ISPE Singapore Conference 2011 aims to address current regulatory, biotech and manufacturing issues which will provide participants with an in-depth learning opportunity and to gain and update industry knowledge.